Lunit and CellCarta Join Forces for Commercialization of AI Biomarker Companion Diagnostics
Deepening Collaboration for Expanded Clinical Trials and Accelerated CDx Launch
On March 30, medical artificial intelligence (AI) company Lunit announced that it has entered into a strategic collaboration with global clinical research organization (CRO) CellCarta to accelerate the commercialization of AI biomarker-based companion diagnostics (CDx).
In September of last year, the two companies formed a partnership to apply Lunit's AI biomarker, "Lunit Scope," to CellCarta's global clinical trial environment. The latest collaboration further advances this initiative, focusing on the development and launch preparation of CDx and supporting their global commercialization.
The companies have agreed to integrate Lunit Scope into CellCarta's clinical workflow to support the following: establishing biomarker strategies, quantitative analysis of immunohistochemistry (IHC), immunophenotyping analysis, clinical trial testing, and preparation for CDx. By doing so, they aim to help pharmaceutical companies enter clinical trials more quickly and expedite CDx launch timelines, thereby supporting the future global commercialization of AI-based biomarker solutions. Additionally, the two companies plan to introduce pilot programs in clinical environments worldwide to expand the use of AI throughout the clinical trial process.
Dusty Tenney, CEO of CellCarta, said, "Pharmaceutical companies want speed and flexibility of choice without compromising quality. By combining CellCarta's global CDx execution capabilities with Lunit's AI solutions, we aim to help pharmaceutical companies advance new drug development quickly."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Beomseok Seo, CEO of Lunit, stated, "For the adoption of AI in the global pharmaceutical and biotech industry, scalability that can be applied to real clinical settings is crucial. Through our collaboration with CellCarta, we will build an integrated AI model to support clinical trials and rapidly drive the commercialization of companion diagnostics."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.